Li H - Search Results

1

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression.

Shang M, Chi Y, Zhang J, Chang J, Yang H, Yin S, Tan Q, Man X, Li H. Shang M, et al. Among authors: li h. Front Oncol. 2022 Jan 5;11:706606. doi: 10.3389/fonc.2021.706606. eCollection 2021. Front Oncol. 2022. PMID: 35070953 Free PMC article.

2

[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].

Ma F, Xu BH, Li HH, Li Q, Zhang P, Yuan P, Wang JY, Fan Y, Li Q. Ma F, et al. Zhonghua Zhong Liu Za Zhi. 2013 Jul;35(7):521-4. Zhonghua Zhong Liu Za Zhi. 2013. PMID: 24257305 Chinese.

3

A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese population.

Li H, Chang C, Shang Y, Qiang L, Zhang B, Bu B, Ren G, Song L, Shang M, Yu J. Li H, et al. Oncotarget. 2017 Oct 16;8(55):94738-94742. doi: 10.18632/oncotarget.21888. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212262 Free PMC article.

4

Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer.

Shang M, Chang C, Pei Y, Guan Y, Chang J, Li H. Shang M, et al. Among authors: li h. J Cancer. 2018 Nov 24;9(24):4627-4634. doi: 10.7150/jca.28458. eCollection 2018. J Cancer. 2018. PMID: 30588246 Free PMC article. Review.

5

Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma.

Dong X, Song J, Chen B, Qi Y, Jiang W, Li H, Zheng D, Wang Y, Zhang X, Liu H. Dong X, et al. Among authors: li h. Front Oncol. 2021 Feb 26;10:592811. doi: 10.3389/fonc.2020.592811. eCollection 2020. Front Oncol. 2021. PMID: 33718105 Free PMC article.

6

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.

Li Y, Qiu Y, Li H, Luo T, Li W, Wang H, Shao B, Wang B, Ge R. Li Y, et al. Among authors: li w, li h. Front Oncol. 2021 Apr 20;11:664429. doi: 10.3389/fonc.2021.664429. eCollection 2021. Front Oncol. 2021. PMID: 33996589 Free PMC article.

7

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study.

Xie Y, Li Y, Ting L, Sang D, Yuan P, Li W, Li H, Ge R, Wang B. Xie Y, et al. Among authors: li y, li w, li h. Front Oncol. 2021 Aug 5;11:699333. doi: 10.3389/fonc.2021.699333. eCollection 2021. Front Oncol. 2021. PMID: 34422652 Free PMC article.

8

Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review.

Chi Y, Shang M, Xu L, Gong H, Tao R, Song L, Zhang B, Yin S, Cong B, Li H. Chi Y, et al. Among authors: li h. Front Oncol. 2022 Feb 16;12:811919. doi: 10.3389/fonc.2022.811919. eCollection 2022. Front Oncol. 2022. PMID: 35251981 Free PMC article. Review.

9

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.

Tan Q, Yin S, Zhou D, Chi Y, Man X, Li H. Tan Q, et al. Among authors: li h. Front Oncol. 2022 Apr 29;12:779786. doi: 10.3389/fonc.2022.779786. eCollection 2022. Front Oncol. 2022. PMID: 35646659 Free PMC article. Review.

10

Clinical features, treatment, and prognosis of 16 breast cancer patients with ocular metastases.

Chang C, Shang Y, Gao Y, Shang M, Wang L, Li H. Chang C, et al. Among authors: li h. Cell Mol Biol (Noisy-le-grand). 2022 Feb 4;67(5):363-370. doi: 10.14715/cmb/2021.67.5.49. Cell Mol Biol (Noisy-le-grand). 2022. PMID: 35818231

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123,401 results

Search Page

Filters